Kane Biotech Inc. (CVE:KNE) Director Acquires C$20,250.00 in Stock

Kane Biotech Inc. (CVE:KNE) Director Marc Edwards bought 150,000 shares of Kane Biotech stock in a transaction that occurred on Monday, July 29th. The stock was purchased at an average price of C$0.14 per share, with a total value of C$20,250.00.

Marc Edwards also recently made the following trade(s):

• On Tuesday, June 25th, Marc Edwards purchased 345,000 shares of Kane Biotech stock. The shares were bought at an average cost of C$0.14 per share, for a total transaction of C$48,300.00.

Kane Biotech Price Performance

Shares of KNE opened at C$0.15 on Thursday. The business’s 50-day moving average is C$0.14 and its two-hundred day moving average is C$0.12. The company has a market capitalization of C$19.88 million, a P/E ratio of -5.00 and a beta of 0.55. The company has a debt-to-equity ratio of 1,164.24, a quick ratio of 0.39 and a current ratio of 0.31. Kane Biotech Inc. has a fifty-two week low of C$0.05 and a fifty-two week high of C$0.17.

Kane Biotech (CVE:KNE) last announced its quarterly earnings results on Thursday, May 23rd. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.05 million during the quarter.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.